Clinical Trials Search Results - National Cancer Institute

Clinical Trials Search Results - National Cancer Institute

1.

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

Status: Active
Phase: Phase III
Type: Prevention
Age: 15 and over
Trial IDs: GHRT01, NCI-2014-02097, NCT01479283

2.

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Status: Active
Phase: Phase III
Type: Supportive care
Age: 13 and over
Trial IDs: P06200, NCI-2013-02285, 2011-003938-14, 5592-069, NCT01782131

3.

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients with Cancer or Undergoing Donor Stem Cell Transplant

Status: Active
Phase: Phase III
Type: Supportive care
Age: 2 months to 21 years
Trial IDs: ACCL1034, NCI-2013-00595, COG-ACCL1034, NCT01817075

4.

Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596

5.

Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Reducing Death or Serious Complications in Patients with Cancer Undergoing Surgery

Status: Active
Phase: Phase III
Type: Health services research, Supportive care
Age: 18 and over
Trial IDs: 14-036, NCI-2014-02262, NCT02456389

6.

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and over
Trial IDs: NV20234, NCI-2009-00978, NCT00545532

7.

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 month to 17 years
Trial IDs: A8851008, NCI-2013-01692, 2008-004150-32, NCT00761267

8.

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AC-061A302, NCI-2014-02194, NCT01983683

9.

RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide

Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: SPI-GCF-301, NCI-2016-00155, NCT02643420

10.

Negative Pressure Wound Therapy in Caring for Women after Abdominal Surgery

Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 15-309, NCI-2016-00514, NCT02682316

11.

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849

12.

Multivirus-Specific T Cells in Preventing or Treating Epstein-Barr Virus, Cytomegalovirus, or Adenovirus Infection After Donor Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: VIRAGE, NCI-2012-00765, H-26374, NCT01070797

13.

Ixazomib Citrate and Peginterferon Alfa-2b in Treating Patients with Metastatic Kidney Cancer

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GU-071, NCI-2015-01878, ERP GU-071, NCT02447887

14.

Donor Multi-virus-Specific Cytotoxic T Lymphocytes in Treating Epstein-Barr Virus, Cytomegalovirus, Adenovirus, Human Herpes Virus 6, and BK Virus Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: Not specified
Trial IDs: H-29966, NCI-2012-02979, ARMS, H-29966 ARMS, NCT01570283

15.

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients with High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 75
Trial IDs: 2241.00, NCI-2009-01334, NCT01008462

16.

Rituximab and Pentostatin or Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0025, NCI-2013-01455, P09576, NCT01059786

17.

Calaspargase Pegol or Pegaspargase in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 365 days to 18 years
Trial IDs: 11-001, NCI-2012-00825, NCT01574274

18.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Previously Treated Advanced Non-small Cell Lung Cancer

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7755, NCI-2012-00865, NCT01620190

19.

Palifermin with Leuprolide Acetate after Total-Body Irradiation Based Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies

Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 to 60
Trial IDs: 12-077, NCI-2012-02983, NCT01746849

20.

Safety Study of Cord Blood Units for Stem Cell Transplants

Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093

21.

Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106

22.

Clofarabine and Melphalan before Donor Stem Cell Transplant in Treating Patients with Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13130, NCI-2013-01193, 107819, 119416, 122471, NCT01885689

23.

Eribulin Mesylate in Treating Patients with Previously Treated Metastatic Breast Cancer

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8093, NCI-2013-01326, NCT01908101

24.

Tumor Infiltrating Lymphocytes, Aldesleukin, Chemotherapy, and Pembrolizumab in Treating Patients with Metastatic Melanoma

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0022, NCI-2014-02337, P131421, NCT01993719

25.

Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 14012, NCI-2014-00639, 105023, 108097, 112566, NCT02094794